Glucagon-like peptide 1 receptor agonists: cardiovascular benefits and mechanisms of action
出版年份 2023 全文链接
标题
Glucagon-like peptide 1 receptor agonists: cardiovascular benefits and mechanisms of action
作者
关键词
-
出版物
Nature Reviews Cardiology
Volume 20, Issue 7, Pages 463-474
出版商
Springer Science and Business Media LLC
发表日期
2023-03-29
DOI
10.1038/s41569-023-00849-3
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Glucagon-Like Peptide 1 Therapy: From Discovery to Type 2 Diabetes and Beyond
- (2023) Adie Viljoen et al. Endocrinology and Metabolism
- Primary Prevention of Cardiovascular and Heart Failure Events With SGLT2 Inhibitors, GLP-1 Receptor Agonists, and Their Combination in Type 2 Diabetes
- (2022) Alison K. Wright et al. DIABETES CARE
- Safety and efficacy of combination therapy with semaglutide, cilofexor and firsocostat in patients with non-alcoholic steatohepatitis: A randomised, open-label phase II trial
- (2022) Naim Alkhouri et al. JOURNAL OF HEPATOLOGY
- Tirzepatide cardiovascular event risk assessment: a pre-specified meta-analysis
- (2022) Naveed Sattar et al. NATURE MEDICINE
- Gliflozins in the Management of Cardiovascular Disease
- (2022) Eugene Braunwald NEW ENGLAND JOURNAL OF MEDICINE
- Glucagon-like Peptide-1 Receptor-based Therapeutics for Metabolic Liver Disease
- (2022) Julian M Yabut et al. ENDOCRINE REVIEWS
- A single dose of exenatide had no effect on blood flow velocity in the middle cerebral artery in elderly healthy volunteers: Randomized, placebo-controlled, double-blind clinical trial
- (2022) Joakim Ölmestig et al. Frontiers in Aging Neuroscience
- Glucagon-Like Peptide-1 Receptor Regulates Thromboxane-Induced Human Platelet Activation
- (2022) Katherine N. Cahill et al. JACC-Basic to Translational Science
- Divergent roles for the gut intraepithelial lymphocyte GLP-1R in control of metabolism, microbiota, and T cell-induced inflammation
- (2022) Chi Kin Wong et al. Cell Metabolism
- Semaglutide improves cardiometabolic risk factors in adults with overweight or obesity: STEP 1 and 4 exploratory analyses
- (2022) Mikhail N. Kosiborod et al. DIABETES OBESITY & METABOLISM
- Glycemia Reduction in Type 2 Diabetes — Microvascular and Cardiovascular Outcomes
- (2022) NEW ENGLAND JOURNAL OF MEDICINE
- Genetic disruption of the Gipr in Apoe−/− mice promotes atherosclerosis
- (2022) Gemma Pujadas et al. Molecular Metabolism
- Impact of intentional weight loss in cardiometabolic disease: what we know about timing of benefits on differing outcomes?
- (2022) Naveed Sattar et al. CARDIOVASCULAR RESEARCH
- Beyond the pancreas: contrasting cardiometabolic actions of GIP and GLP1
- (2022) Rola Hammoud et al. Nature Reviews Endocrinology
- Semaglutide for cardiovascular event reduction in people with overweight or obesity: SELECT study baseline characteristics
- (2022) Ildiko Lingvay et al. Obesity
- Pharmacogenomics of GLP-1 receptor agonists: a genome-wide analysis of observational data and large randomised controlled trials
- (2022) Adem Y Dawed et al. Lancet Diabetes & Endocrinology
- Glucagon-like Peptide-1 receptor Tie2+ cells are essential for the cardioprotective actions of liraglutide in mice with experimental myocardial infarction
- (2022) Brent A. McLean et al. Molecular Metabolism
- Risk of stroke and retinopathy during GLP-1 receptor agonist cardiovascular outcome trials: An eight RCTs meta-analysis
- (2022) Jinjing Wei et al. Frontiers in Endocrinology
- The Effect of Exenatide Once Weekly on Carotid Atherosclerosis in Individuals With Type 2 Diabetes: An 18-Month Randomized Placebo-Controlled Study
- (2021) Juraj Koska et al. DIABETES CARE
- Dulaglutide exerts beneficial anti atherosclerotic effects in ApoE knockout mice with diabetes: the earlier, the better
- (2021) Junpei Sanada et al. Scientific Reports
- Cardiac Energy Metabolism in Heart Failure
- (2021) Gary D. Lopaschuk et al. CIRCULATION RESEARCH
- Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2·4 mg for weight management: a randomised, controlled, phase 1b trial
- (2021) Lone B Enebo et al. LANCET
- Effect of Liraglutide on Arterial Inflammation Assessed as [ 18 F]FDG Uptake in Patients With Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Trial
- (2021) Rasmus S. Ripa et al. Circulation-Cardiovascular Imaging
- Danuglipron (PF-06882961) in type 2 diabetes: a randomized, placebo-controlled, multiple ascending-dose phase 1 trial
- (2021) Aditi R. Saxena et al. NATURE MEDICINE
- Cardiovascular and Renal Outcomes with Efpeglenatide in Type 2 Diabetes
- (2021) Hertzel C. Gerstein et al. NEW ENGLAND JOURNAL OF MEDICINE
- Subcutaneous infusion of exenatide and cardiovascular outcomes in type 2 diabetes: a non-inferiority randomized controlled trial
- (2021) Christian T. Ruff et al. NATURE MEDICINE
- Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials
- (2021) Naveed Sattar et al. Lancet Diabetes & Endocrinology
- Differential importance of endothelial and hematopoietic cell GLP-1Rs for cardiometabolic versus hepatic actions of semaglutide
- (2021) Brent A. McLean et al. JCI Insight
- GLP-1 physiology informs the pharmacotherapy of obesity
- (2021) Daniel J. Drucker Molecular Metabolism
- The GLP-1R agonist liraglutide increases myocardial glucose oxidation rates via indirect mechanisms and mitigates experimental diabetic cardiomyopathy
- (2020) Malak Almutairi et al. CANADIAN JOURNAL OF CARDIOLOGY
- Cardiovascular Risk Reduction With Liraglutide: An Exploratory Mediation Analysis of the LEADER Trial
- (2020) John B. Buse et al. DIABETES CARE
- Effects of Liraglutide on Cardiovascular Outcomes in Patients With Diabetes With or Without Heart Failure
- (2020) Steven P. Marso et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- The effects of liraglutide and dapagliflozin on cardiac function and structure in a multi-hit mouse model of Heart Failure with Preserved Ejection Fraction
- (2020) Coenraad Withaar et al. CARDIOVASCULAR RESEARCH
- Glucagon-like peptide-1 receptor co-agonists for treating metabolic disease
- (2020) Laurie L. Baggio et al. Molecular Metabolism
- Revisiting the Complexity of GLP-1 Action from Sites of Synthesis to Receptor Activation
- (2020) Brent A McLean et al. ENDOCRINE REVIEWS
- Effect of liraglutide on body weight and microvascular function in non-diabetic overweight women with coronary microvascular dysfunction
- (2019) Hannah Elena Suhrs et al. INTERNATIONAL JOURNAL OF CARDIOLOGY
- Determining the Effects of Combined Liraglutide and Phentermine on Metabolic Parameters, Blood Pressure, and Heart Rate in Lean and Obese Male Mice
- (2019) Stephanie E. Simonds et al. DIABETES
- Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial
- (2019) Hertzel C Gerstein et al. LANCET
- Oral Semaglutide Versus Empagliflozin in Patients With Type 2 Diabetes Uncontrolled on Metformin: The PIONEER 2 Trial
- (2019) Helena W. Rodbard et al. DIABETES CARE
- Glucagon-like peptide 1 (GLP-1)
- (2019) T.D. Müller et al. Molecular Metabolism
- Glucose-dependent insulinotropic polypeptide (GIP) and cardiovascular disease
- (2019) Sebastian M. Heimbürger et al. PEPTIDES
- Endothelial GLP-1 (Glucagon-Like Peptide-1) Receptor Mediates Cardiovascular Protection by Liraglutide In Mice With Experimental Arterial Hypertension
- (2019) Johanna Helmstädter et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- Inactivation of the Glucose-Dependent Insulinotropic Polypeptide Receptor Improves Outcomes following Experimental Myocardial Infarction
- (2018) John R. Ussher et al. Cell Metabolism
- Endocardial Cell Plasticity in Cardiac Development, Diseases and Regeneration
- (2018) Hui Zhang et al. CIRCULATION RESEARCH
- Glucagon-like peptide-1 receptor agonists reduced the low-density lipoprotein cholesterol in Japanese patients with type 2 diabetes mellitus treated with statins
- (2018) Yukiko Hasegawa et al. Journal of Clinical Lipidology
- Impact of intravenous exenatide infusion for perioperative blood glucose control on myocardial ischemia-reperfusion injuries after coronary artery bypass graft surgery: sub study of the phase II/III ExSTRESS randomized trial
- (2018) Guillaume Besch et al. Cardiovascular Diabetology
- Effects of Liraglutide on Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus With or Without History of Myocardial Infarction or Stroke
- (2018) Subodh Verma et al. CIRCULATION
- Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial
- (2018) Adrian F Hernandez et al. LANCET
- GLP‐1 Is a Coronary Artery Vasodilator in Humans
- (2018) Sophie J. Clarke et al. Journal of the American Heart Association
- Effect of liraglutide on myocardial glucose uptake and blood flow in stable chronic heart failure patients: A double-blind, randomized, placebo-controlled LIVE sub-study
- (2017) Roni Nielsen et al. JOURNAL OF NUCLEAR CARDIOLOGY
- Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes
- (2017) Rury R. Holman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Enteroendocrine L Cells Sense LPS after Gut Barrier Injury to Enhance GLP-1 Secretion
- (2017) Lorène J. Lebrun et al. Cell Reports
- Liraglutide improves metabolic parameters and carotid intima-media thickness in diabetic patients with the metabolic syndrome: an 18-month prospective study
- (2016) Manfredi Rizzo et al. Cardiovascular Diabetology
- The Cardiovascular Biology of Glucagon-like Peptide-1
- (2016) Daniel J. Drucker Cell Metabolism
- Suppressive Effects of Glucose-Dependent Insulinotropic Polypeptide on Cardiac Hypertrophy and Fibrosis in Angiotensin II-Infused Mouse Models
- (2016) Munenori Hiromura et al. CIRCULATION JOURNAL
- Effect of liraglutide, a glucagon-like peptide-1 analogue, on left ventricular function in stable chronic heart failure patients with and without diabetes (LIVE)-a multicentre, double-blind, randomised, placebo-controlled trial
- (2016) Anders Jorsal et al. EUROPEAN JOURNAL OF HEART FAILURE
- No benefit of additional treatment with exenatide in patients with an acute myocardial infarction
- (2016) Sebastiaan T. Roos et al. INTERNATIONAL JOURNAL OF CARDIOLOGY
- Effects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction
- (2016) Kenneth B. Margulies et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
- (2016) Steven P. Marso et al. NEW ENGLAND JOURNAL OF MEDICINE
- Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
- (2016) Steven P. Marso et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effects of the Novel Long-Acting GLP-1 Agonist, Albiglutide, on Cardiac Function, Cardiac Metabolism, and Exercise Capacity in Patients With Chronic Heart Failure and Reduced Ejection Fraction
- (2016) John J. Lepore et al. JACC-Heart Failure
- Effects of liraglutide on left ventricular function in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention
- (2015) Wei Ren Chen et al. AMERICAN HEART JOURNAL
- Caveolins in cardioprotection - translatability and mechanisms
- (2015) Jan M Schilling et al. BRITISH JOURNAL OF PHARMACOLOGY
- GLP-1R Agonists Modulate Enteric Immune Responses Through the Intestinal Intraepithelial Lymphocyte GLP-1R
- (2015) Bernardo Yusta et al. DIABETES
- Inhibition of Dipeptidyl Peptidase-4 Impairs Ventricular Function and Promotes Cardiac Fibrosis in High Fat–Fed Diabetic Mice
- (2015) Erin E. Mulvihill et al. DIABETES
- Exenatide exerts a PKA-dependent positive inotropic effect in human atrial myocardium
- (2015) Markus Wallner et al. JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY
- Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome
- (2015) Marc A. Pfeffer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cardioprotection Resulting from Glucagon-Like Peptide-1 Administration Involves Shifting Metabolic Substrate Utilization to Increase Energy Efficiency in the Rat Heart
- (2015) Karpagam Aravindhan et al. PLoS One
- Type 2 diabetes and incidence of cardiovascular diseases: a cohort study in 1·9 million people
- (2015) Anoop Dinesh Shah et al. Lancet Diabetes & Endocrinology
- Exendin-4 ameliorates cardiac ischemia/reperfusion injury via caveolae and caveolins-3
- (2014) Yasuo M Tsutsumi et al. Cardiovascular Diabetology
- Changes in liraglutide-induced body composition are related to modifications in plasma cardiac natriuretic peptides levels in obese type 2 diabetic patients
- (2014) Chun-Jun Li et al. Cardiovascular Diabetology
- Cardiovascular Actions of Incretin-Based Therapies
- (2014) John R. Ussher et al. CIRCULATION RESEARCH
- Impact of Acute Hyperglycemia on Myocardial Infarct Size, Area at Risk, and Salvage in Patients With STEMI and the Association With Exenatide Treatment: Results From a Randomized Study
- (2014) J. Lonborg et al. DIABETES
- The effect of liraglutide on endothelial function in patients with type 2 diabetes
- (2014) Debashis Nandy et al. Diabetes & Vascular Disease Research
- Liraglutide Promotes Natriuresis but Does Not Increase Circulating Levels of Atrial Natriuretic Peptide in Hypertensive Subjects With Type 2 Diabetes
- (2014) Julie A. Lovshin et al. DIABETES CARE
- Pharmacology, Physiology, and Mechanisms of Action of Dipeptidyl Peptidase-4 Inhibitors
- (2014) Erin E. Mulvihill et al. ENDOCRINE REVIEWS
- Reductions in systolic blood pressure with liraglutide in patients with type 2 diabetes: Insights from a patient-level pooled analysis of six randomized clinical trials
- (2014) Vivian A. Fonseca et al. JOURNAL OF DIABETES AND ITS COMPLICATIONS
- GLP-1 increases microvascular recruitment but not glucose uptake in human and rat skeletal muscle
- (2013) Kim A. Sjøberg et al. AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM
- Cardioprotective Effects of Exenatide in Patients With ST-Segment–Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention
- (2013) Jong Shin Woo et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- Pharmacology, Physiology, and Mechanisms of Incretin Hormone Action
- (2013) Jonathan E. Campbell et al. Cell Metabolism
- Identification and Characterization of GLP-1 Receptor-Expressing Cells Using a New Transgenic Mouse Model
- (2013) P. Richards et al. DIABETES
- GLP-1 receptor activation and Epac2 link atrial natriuretic peptide secretion to control of blood pressure
- (2013) Minsuk Kim et al. NATURE MEDICINE
- Protein kinase A mediates glucagon-like peptide 1-induced nitric oxide production and muscle microvascular recruitment
- (2012) Zhenhua Dong et al. AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM
- Effects of Exenatide vs. Metformin on endothelial function in obese patients with pre-diabetes: a randomized trial
- (2012) Aaron S Kelly et al. Cardiovascular Diabetology
- A Glucagon-Like Peptide-1 Analog Reverses the Molecular Pathology and Cardiac Dysfunction of a Mouse Model of Obesity
- (2012) Mohammad Hossein Noyan-Ashraf et al. CIRCULATION
- Exenatide Reduces Final Infarct Size in Patients With ST-Segment–Elevation Myocardial Infarction and Short-Duration of Ischemia
- (2012) Jacob Lønborg et al. Circulation-Cardiovascular Interventions
- Glucagon-Like Peptide 1 Recruits Microvasculature and Increases Glucose Use in Muscle via a Nitric Oxide-Dependent Mechanism
- (2012) W. Chai et al. DIABETES
- Cardiovascular Biology of the Incretin System
- (2012) John R. Ussher et al. ENDOCRINE REVIEWS
- GLP-1 Receptor Activation Indirectly Reduces Hepatic Lipid Accumulation But Does Not Attenuate Development of Atherosclerosis in Diabetic MaleApoE−/−Mice
- (2012) Naim Panjwani et al. ENDOCRINOLOGY
- The Glucagon-Like Peptide-1 Receptor—or Not?
- (2012) Charles Pyke et al. ENDOCRINOLOGY
- Glucose-Dependent Insulinotropic Polypeptide Prevents the Progression of Macrophage-Driven Atherosclerosis in Diabetic Apolipoprotein E-Null Mice
- (2012) Yukinori Nogi et al. PLoS One
- Exenatide reduces reperfusion injury in patients with ST-segment elevation myocardial infarction
- (2011) Jacob Lønborg et al. EUROPEAN HEART JOURNAL
- Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide
- (2011) A Astrup et al. INTERNATIONAL JOURNAL OF OBESITY
- Exenatide Exerts a Potent Antiinflammatory Effect
- (2011) Ajay Chaudhuri et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Cardiovascular safety and diabetes drug development
- (2011) Daniel J Drucker et al. LANCET
- Albiglutide, a Long Lasting Glucagon-Like Peptide-1 Analog, Protects the Rat Heart against Ischemia/Reperfusion Injury: Evidence for Improving Cardiac Metabolic Efficiency
- (2011) Weike Bao et al. PLoS One
- Glucagon-Like Peptide-1 Increases Myocardial Glucose Uptake via p38α MAP Kinase–Mediated, Nitric Oxide–Dependent Mechanisms in Conscious Dogs With Dilated Cardiomyopathy
- (2010) Siva Bhashyam et al. Circulation-Heart Failure
- Inhibition of Monocyte Adhesion to Endothelial Cells and Attenuation of Atherosclerotic Lesion by a Glucagon-like Peptide-1 Receptor Agonist, Exendin-4
- (2010) M. Arakawa et al. DIABETES
- DURATION-1: Exenatide Once Weekly Produces Sustained Glycemic Control and Weight Loss Over 52 Weeks
- (2010) J. B. Buse et al. DIABETES CARE
- Exendin-4 has an anti-hypertensive effect in salt-sensitive mice model
- (2009) Kunio Hirata et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Lack of cardioprotection from subcutaneously and preischemic administered Liraglutide in a closed chest porcine ischemia reperfusion model
- (2009) Jens Kristensen et al. BMC Cardiovascular Disorders
- GLP-1R Agonist Liraglutide Activates Cytoprotective Pathways and Improves Outcomes After Experimental Myocardial Infarction in Mice
- (2009) M. H. Noyan-Ashraf et al. DIABETES
- Exenatide Reduces Infarct Size and Improves Cardiac Function in a Porcine Model of Ischemia and Reperfusion Injury
- (2009) Leo Timmers et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Identification of Potential Pharmacological Targets by Analysis of the Comprehensive G Protein-Coupled Receptor Repertoire in the Four Cardiac Chambers
- (2009) T. Moore-Morris et al. MOLECULAR PHARMACOLOGY
- Cardioprotective and Vasodilatory Actions of Glucagon-Like Peptide 1 Receptor Are Mediated Through Both Glucagon-Like Peptide 1 Receptor–Dependent and –Independent Pathways
- (2008) Kiwon Ban et al. CIRCULATION
- Chronic Glucagon-Like Peptide-1 Infusion Sustains Left Ventricular Systolic Function and Prolongs Survival in the Spontaneously Hypertensive, Heart Failure–Prone Rat
- (2008) Indu Poornima et al. Circulation-Heart Failure
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started